• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

可待因O-去甲基化与多态性异喹胍羟基化共分离。

Codeine O-demethylation co-segregates with polymorphic debrisoquine hydroxylation.

作者信息

Yue Q Y, Svensson J O, Alm C, Sjöqvist F, Säwe J

机构信息

Department of Clinical Pharmacology, Karolinska Institute, Huddinge University Hospital, Sweden.

出版信息

Br J Clin Pharmacol. 1989 Dec;28(6):639-45. doi: 10.1111/j.1365-2125.1989.tb03556.x.

DOI:10.1111/j.1365-2125.1989.tb03556.x
PMID:2611086
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1380034/
Abstract
  1. A single oral dose of codeine (25 mg) was given to 132 healthy Swedish Caucasians who had previously been phenotyped with respect to debrisoquine hydroxylation. The 'metabolic ratios' (MR) in urine of codeine O-demethylation (codeine/(morphine (M) + morphine-3- and 6-glucuronides (M3G and M6G) + normorphine], N-demethylation (codeine/(norcodeine (NC) + norcodeine glucuronide + normorphine (NM]) and glucuronidation (codeine/codeine-6-glucuronide (C6G] were calculated following h.p.l.c. analysis of urine samples collected over 8 h. 2. There was a significant correlation between the log MR for debrisoquine hydroxylation and the log MR for codeine O-demethylation (rs = 0.77, P less than 0.001). The poor debrisoquine hydroxylators had MRs of codeine O-demethylation between 8.3 and 55.1, while the values for extensive hydroxylators were between 0.4 and 5.5. 3. The poor debrisoquine hydroxylators excreted significantly less M, M3G, M6G and NM, while the urinary recovery of C6G and NC was significantly higher in these subjects compared to the extensive hydroxylators. 4. The MRs for glucuronidation and N-demethylation did not exhibit a bimodal distribution, and were not related to the MR of debrisoquine hydroxylation. 5. No associations were found between sex, body-weight, smoking habits, age, urine volume or urine pH and the O-demethylation of codeine. 6. The O-demethylation of codeine to form M appears to be under the same polymorphic genetic control as the 4-hydroxylation of debrisoquine.
摘要
  1. 给132名健康的瑞典高加索人单次口服25毫克可待因,这些人之前已就异喹胍羟基化进行了表型分析。在对8小时内收集的尿液样本进行高效液相色谱分析后,计算可待因O-去甲基化(可待因/[吗啡(M)+吗啡-3-和6-葡萄糖醛酸苷(M3G和M6G)+去甲吗啡])、N-去甲基化(可待因/[去甲可待因(NC)+去甲可待因葡萄糖醛酸苷+去甲吗啡(NM)])和葡萄糖醛酸化(可待因/可待因-6-葡萄糖醛酸苷(C6G))的“代谢比”(MR)。

  2. 异喹胍羟基化的对数MR与可待因O-去甲基化的对数MR之间存在显著相关性(rs = 0.77,P < 0.001)。异喹胍羟基化能力差的个体,其可待因O-去甲基化的MR在8.3至55.1之间,而羟基化能力强的个体该值在0.4至5.5之间。

  3. 异喹胍羟基化能力差的个体排泄的M、M3G、M6G和NM显著减少,而与羟基化能力强的个体相比,这些受试者尿液中C6G和NC的回收率显著更高。

  4. 葡萄糖醛酸化和N-去甲基化的MR未呈现双峰分布,且与异喹胍羟基化的MR无关。

  5. 在性别、体重、吸烟习惯、年龄、尿量或尿液pH与可待因的O-去甲基化之间未发现关联。

  6. 可待因O-去甲基化形成M似乎与异喹胍4-羟基化受相同的多态性遗传控制。

相似文献

1
Codeine O-demethylation co-segregates with polymorphic debrisoquine hydroxylation.可待因O-去甲基化与多态性异喹胍羟基化共分离。
Br J Clin Pharmacol. 1989 Dec;28(6):639-45. doi: 10.1111/j.1365-2125.1989.tb03556.x.
2
Pharmacokinetics of codeine and its metabolites in Caucasian healthy volunteers: comparisons between extensive and poor hydroxylators of debrisoquine.可待因及其代谢产物在高加索健康志愿者体内的药代动力学:异喹胍强代谢型与弱代谢型的比较。
Br J Clin Pharmacol. 1991 Jun;31(6):635-42. doi: 10.1111/j.1365-2125.1991.tb05585.x.
3
Interindividual and interethnic differences in the demethylation and glucuronidation of codeine.可待因去甲基化和葡萄糖醛酸化的个体间及种族间差异。
Br J Clin Pharmacol. 1989 Dec;28(6):629-37. doi: 10.1111/j.1365-2125.1989.tb03555.x.
4
The effect of codeine on gastrointestinal transit in extensive and poor metabolisers of debrisoquine.可待因对异喹胍广泛代谢者和代谢不良者胃肠道转运的影响。
Eur J Clin Pharmacol. 1997;53(2):145-8. doi: 10.1007/s002280050353.
5
Indices and graphical approaches for the detection of interindividual and interethnic variations in codeine metabolism.用于检测可待因代谢个体间和种族间差异的指标及图形方法。
Br J Clin Pharmacol. 1997 Sep;44(3):239-44. doi: 10.1046/j.1365-2125.1997.t01-1-00571.x.
6
Quantification of the O- and N-demethylated and the glucuronidated metabolites of codeine relative to the debrisoquine metabolic ratio in urine in ultrarapid, rapid, and poor debrisoquine hydroxylators.
Ther Drug Monit. 1997 Oct;19(5):539-42. doi: 10.1097/00007691-199710000-00010.
7
Relationship of N-demethylation of amiflamine and its metabolite to debrisoquine hydroxylation polymorphism.
Clin Pharmacol Ther. 1984 Oct;36(4):515-9. doi: 10.1038/clpt.1984.212.
8
A comparison of the pharmacokinetics of codeine and its metabolites in healthy Chinese and Caucasian extensive hydroxylators of debrisoquine.可待因及其代谢产物在健康中国人和白种人强异喹胍羟基化者体内的药代动力学比较。
Br J Clin Pharmacol. 1991 Jun;31(6):643-7. doi: 10.1111/j.1365-2125.1991.tb05586.x.
9
E- and Z-10-hydroxylation of nortriptyline: relationship to polymorphic debrisoquine hydroxylation.去甲替林的E型和Z型10-羟基化作用:与异喹胍多态性羟基化作用的关系。
Clin Pharmacol Ther. 1981 Aug;30(2):189-93. doi: 10.1038/clpt.1981.147.
10
On the assessment of drug metabolism by assays of codeine and its main metabolites.通过可待因及其主要代谢物的测定评估药物代谢
Ther Drug Monit. 2000 Jun;22(3):258-65. doi: 10.1097/00007691-200006000-00005.

引用本文的文献

1
CYP2D6 pharmacogenetics and phenoconversion in personalized medicine.CYP2D6 药物遗传学和个体化医学中的表型转化。
Expert Opin Drug Metab Toxicol. 2022 Nov;18(11):769-785. doi: 10.1080/17425255.2022.2160317. Epub 2023 Jan 3.
2
Perspectives from the Society for Pediatric Research: pharmacogenetics for pediatricians.儿科研究学会观点:儿科医生的药物遗传学。
Pediatr Res. 2022 Feb;91(3):529-538. doi: 10.1038/s41390-021-01499-2. Epub 2021 Apr 6.
3
Functional phenotyping of the CYP2D6 probe drug codeine in the horse.马 CYP2D6 探针药物可待因的功能表型分析。
BMC Vet Res. 2021 Feb 13;17(1):77. doi: 10.1186/s12917-021-02788-y.
4
Gene-Based Dose Optimization in Children.基于基因的儿童剂量优化。
Annu Rev Pharmacol Toxicol. 2020 Jan 6;60:311-331. doi: 10.1146/annurev-pharmtox-010919-023459. Epub 2019 Jul 5.
5
Clinical Pharmacogenetics of Cytochrome P450-Associated Drugs in Children.儿童中细胞色素P450相关药物的临床药物遗传学
J Pers Med. 2017 Nov 2;7(4):14. doi: 10.3390/jpm7040014.
6
Influence of the CYP2D6 polymorphism and hemodialysis on codeine disposition in patients with end-stage renal disease.CYP2D6 多态性和血液透析对终末期肾病患者中可待因处置的影响。
Eur J Clin Pharmacol. 2010 Mar;66(3):269-73. doi: 10.1007/s00228-009-0759-8. Epub 2009 Nov 26.
7
CYP induction-mediated drug interactions: in vitro assessment and clinical implications.细胞色素P450酶诱导介导的药物相互作用:体外评估及临床意义
Pharm Res. 2006 Jun;23(6):1089-116. doi: 10.1007/s11095-006-0277-7. Epub 2006 May 26.
8
Genetic predictors of the clinical response to opioid analgesics: clinical utility and future perspectives.阿片类镇痛药临床反应的遗传预测因素:临床应用及未来展望。
Clin Pharmacokinet. 2004;43(14):983-1013. doi: 10.2165/00003088-200443140-00003.
9
Pharmacokinetic interactions with rifampicin : clinical relevance.与利福平的药代动力学相互作用:临床相关性。
Clin Pharmacokinet. 2003;42(9):819-50. doi: 10.2165/00003088-200342090-00003.
10
Strategies and molecular probes to investigate the role of cytochrome P450 in drug metabolism: focus on in vitro studies.研究细胞色素P450在药物代谢中作用的策略和分子探针:聚焦于体外研究
Clin Pharmacokinet. 2003;42(2):153-78. doi: 10.2165/00003088-200342020-00004.

本文引用的文献

1
Analgesic potency of normorphine in patients with postoperative pain.
J Pharmacol Exp Ther. 1958 Nov;124(3):260-3.
2
The metabolic fate of codeine in man.可待因在人体内的代谢转归
J Pharmacol Exp Ther. 1955 Jul;114(3):251-62.
3
The effect of N-demethylation on certain pharmacologic actions of morphine, codeine, and meperidine in the mouse.N-去甲基化对小鼠体内吗啡、可待因和哌替啶某些药理作用的影响。
J Pharmacol Exp Ther. 1954 Oct;112(2):191-6.
4
A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population.对英国白人人群中异喹胍氧化遗传多态性的家系及群体研究。
J Med Genet. 1980 Apr;17(2):102-5. doi: 10.1136/jmg.17.2.102.
5
Determination of morphine, morphine-3-glucuronide and (tentatively) morphine-6-glucuronide in plasma and urine using ion-pair high-performance liquid chromatography.采用离子对高效液相色谱法测定血浆和尿液中的吗啡、吗啡-3-葡萄糖醛酸苷以及(初步测定)吗啡-6-葡萄糖醛酸苷。
J Chromatogr. 1982 Jul 9;230(2):427-32. doi: 10.1016/s0378-4347(00)80494-6.
6
Codeine disposition in smokers and nonsmokers.可待因在吸烟者和非吸烟者体内的代谢情况。
Clin Pharmacol Ther. 1982 Aug;32(2):218-27. doi: 10.1038/clpt.1982.151.
7
Polymorphic oxidation of sparteine and debrisoquine: related pharmacogenetic entities.鹰爪豆碱和异喹胍的多态性氧化:相关药物遗传学实体。
Clin Pharmacol Ther. 1982 Feb;31(2):184-6. doi: 10.1038/clpt.1982.29.
8
Mephenytoin hydroxylation deficiency in Caucasians: frequency of a new oxidative drug metabolism polymorphism.高加索人中美芬妥英羟化缺乏症:一种新的氧化药物代谢多态性的频率
Clin Pharmacol Ther. 1984 Dec;36(6):773-80. doi: 10.1038/clpt.1984.256.
9
Pharmacogenetics of mephenytoin: a new drug hydroxylation polymorphism in man.美芬妥英的药物遗传学:人类一种新的药物羟基化多态性
Eur J Clin Pharmacol. 1984;26(6):753-9. doi: 10.1007/BF00541938.
10
Human cytochromes P-450.人类细胞色素P-450
Xenobiotica. 1984 Jan-Feb;14(1-2):151-85. doi: 10.3109/00498258409151404.